Tascenso Odt is a drug owned by Cycle Pharmaceuticals Ltd. It is protected by 3 US drug patents filed from 2021 to 2022 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 19, 2036. Details of Tascenso Odt's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10555902 | Stable fingolimod dosage forms |
Jan, 2036
(11 years from now) | Active |
| US9925138 | Stable solid fingolimod dosage forms |
Jan, 2036
(11 years from now) | Active |
| US10925829 | Stable solid fingolimod dosage forms |
Jan, 2036
(11 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tascenso Odt's patents.
Latest Legal Activities on Tascenso Odt's Patents
Given below is the list of recent legal activities going on the following patents of Tascenso Odt.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 05 Jul, 2023 | US10555902 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 25 Jun, 2021 | US9925138 |
| Recordation of Patent Grant Mailed Critical | 23 Feb, 2021 | US10925829 |
| Patent Issue Date Used in PTA Calculation Critical | 23 Feb, 2021 | US10925829 |
| Email Notification Critical | 04 Feb, 2021 | US10925829 |
| Issue Notification Mailed Critical | 03 Feb, 2021 | US10925829 |
| Application Is Considered Ready for Issue Critical | 20 Jan, 2021 | US10925829 |
| Dispatch to FDC | 20 Jan, 2021 | US10925829 |
| Issue Fee Payment Received Critical | 19 Jan, 2021 | US10925829 |
| Issue Fee Payment Verified Critical | 19 Jan, 2021 | US10925829 |
US patents provide insights into the exclusivity only within the United States, but Tascenso Odt is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tascenso Odt's family patents as well as insights into ongoing legal events on those patents.
Tascenso Odt's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tascenso Odt's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 19, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tascenso Odt Generics:
There are no approved generic versions for Tascenso Odt as of now.
About Tascenso Odt
Tascenso Odt is a drug owned by Cycle Pharmaceuticals Ltd. It is used for treating relapsing forms of multiple sclerosis in pediatric patients 10 years of age and older. Tascenso Odt uses Fingolimod Lauryl Sulfate as an active ingredient. Tascenso Odt was launched by Cycle in 2021.
Approval Date:
Tascenso Odt was approved by FDA for market use on 23 December, 2021.
Active Ingredient:
Tascenso Odt uses Fingolimod Lauryl Sulfate as the active ingredient. Check out other Drugs and Companies using Fingolimod Lauryl Sulfate ingredient
Treatment:
Tascenso Odt is used for treating relapsing forms of multiple sclerosis in pediatric patients 10 years of age and older.
Dosage:
Tascenso Odt is available in tablet, orally disintegrating form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.25MG BASE | TABLET, ORALLY DISINTEGRATING | Prescription | ORAL |
| EQ 0.5MG BASE | TABLET, ORALLY DISINTEGRATING | Prescription | ORAL |